N/A N=14 Vascular Dysfunction During Physical Inactivity
Aging · Vascular Endothelium · Skeletal Muscle
Primary: Brachial Artery Vascular Function — 5.1; 3.1; 4.4 percent vasodilation
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=225 Vitamin D and Vascular Health in Children
Obesity · Vitamin D Deficiency
Primary: Flow-mediated Dilation (FMD) Percentage — 7.61; 8.27; 7.31 percentage of baseline dilation — p=0.88
Phase 2 N=15 Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change in Flow Mediated Dilation — 0.26; -1.5 percentage of flow mediated dilation
Phase 2 N=12 Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
N/A N=125 Non-invasive Computer-Aided Phenotyping of Vasculopathy
Carotid Atherosclerosis · Peripheral Arterial Disease
Primary: Measurement Bias of Calcification Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth. — -0.47; .07 mm2
Phase 2 N=34 Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Metabolic Syndrome · Coronary Microvascular Dysfunction
Primary: Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI) — -1.11; 0.40 mm^2 — p=0.0005
Phase 3 N=24 Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Glygocalyx Integrity - Perfused Boundary Region — 0.11; -0.16 Delta micrometers (mcm)
Phase 2 N=19 Blood Flow and Vascular Function in Cystic Fibrosis
Cystic Fibrosis
Primary: Acute Study: Percentage Flow-Mediated Dilation (FMD) — 7.8; 7.7; 7.3; 6.6 percent flow mediated dilation
N/A N=91 Microvascular Blood Flow in Sickle Cell Anemia
Sickle Cell Disease · Sickle Cell Anemia
Primary: Microvascular Blood Flow Rate Change — 1.09; 0.86 Ratio of change
N/A N=130 Effect of Vitamin D3 on Vascular Function
Vitamin D Deficiency
Primary: Pulse Wave Velocity for Vascular Stiffness — 29.3; 27.6 m/s
N/A N=338 Vascular Risk After Kidney Transplantation
Cardiovascular Disease · Chronic Kidney Disease · Diabetes
Primary: Carotid Intima Media Thickness (CIMT) — 0.044 millimeters (mm)
N/A N=41 Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo
Chronic Kidney Disease
Primary: Change in Circulating ICAM-1 Shown by Absolute Values at Baseline, Day 28 and Day 56 — 707; 701; 679; 627 nanogram/ml — p=>0.05
N/A N=16 Differential Diagnosis for the Causes of Subclavian Steal for Patients With Vascular Access in the Forearm
Subclavian Steal
Primary: Change of Subclavian Flow to Normal Flow Pattern During Cuff Test — 0; 2 participants
N/A N=4 Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
N/A N=246 Platelet Activity in Vascular Surgery and Cardiovascular Events
Cardiovascular Disease · Peripheral Artery Disease · Critical Limb Ischemia
Primary: Number of Patients in Which Platelet Activity Measurements Were Associated With Short-term Cardiovascular Events — 31; 16 participants
N/A N=12,012 Vascular Ultrasound Screening in Patients With Ischemic Cerebrovascular Disease: a Multi-center Registry Study
Stroke
Primary: Evidence of Carotid Artery or Intracranial Artery Atherosclerosis Confirmed by Vascular Ultrasonography — 96; 1063; 826; 241 artery numbers
N/A N=202 Dietary Intervention and Vascular Function
Cardiovascular Disease
Primary: Percent Change in Flow Mediated Dilatation (FMD) — -0.39; -0.07; -0.08 post-occlusion diameter change as % — p=0.238
N/A N=99 Effects of Walking and Heating on Vascular Function in Diabetic Patients
Type 2 Diabetes Mellitus · Obesity
Primary: Insulin-stimulated Leg Blood Flow Calculated as Percent Change (t0, t60) — 133.6; 8.92 percentage change
N/A N=125 Vitamin D, Insulin Resistance, and Cardiovascular Disease
Vitamin D Deficiency · Insulin Resistance · Type 2 Diabetes Mellitus
Primary: Hypertension (24h Blood Pressure, Central Blood Pressure, and Office BP) — 126.6; 131.1; 79.2; 78.9 mm Hg
N/A N=89 Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People
HIV Infection
Primary: Endothelial Function (Brachial Artery Reactivity) — 3.98; 3.37 percent dilation — p=0.10
N/A N=35 Exercise Rehabilitation in Veterans With PAD
Peripheral Arterial Disease · Intermittent Claudication
Primary: Modified Physical Performance Test — 31.8; 32.3 scores on a scale
N/A N=20 Sex Differences in Vascular Responses to Exercise
Aging
Primary: Change in FMD in Response to Chronic HIIT — 0.11; 0.57; 0.81; 0.10 % flow mediated dilation
Phase 4 N=42 Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)
Renal Insufficiency, Chronic
Primary: Change in Flow-mediated Dilation (FMD) — 1.1; -0.9 change in percent flow-mediated dilation
N/A N=23 Long Sleep Duration and Vascular Function
Sleep
Primary: Change From Wake in Central Aortic Pulse Pressure After 11 Hours in Bed — -1.5; 0.5 mm Hg — p=0.36
N/A N=34 Vasculera in Participants With Lipedema
Lipedema
Primary: Change in Weight From Baseline — 0.340 kilograms — p=0.473
N/A N=52 Vitamin D and Arteriovenous Fistulae
End-stage Renal Disease
Primary: Arteriovenous Fistulae Maturation — 50; 40 percentage of group
N/A N=20 Metabolic Acidosis and Vascular Function in Patients With Chronic Kidney Disease
Metabolic Acidosis · Chronic Kidney Disease
Primary: Change in Brachial Artery Flow Mediated Dilation (FMD) — 1.1; -0.7 absolute change in percent FMD
Phase 3 N=128 Vitamin D and Arterial Function in Patients With Chronic Kidney Disease
Arterial Dysfunction · Chronic Kidney Disease
Primary: Compare the Difference Between the Calcitriol and Cholecalciferol Groups in Conduit Artery Endothelium-dependent Dilation (EDD) in Response to Treatment. — -0.5; 0.3…
Phase 4 N=24 Testosterone for Peripheral Vascular Disease
Hypogonadism · Peripheral Vascular Disease · Type 2 Diabetes
Primary: Change in Arterial Stiffness — 15.02; 15.08; 14.08; 16.12 index β
N/A N=52 VASCADE ANTEGRADE-PVD Post-Market Registry
Surgical Wound
Primary: Time to Hemostasis (TTH) — 5.87 minutes